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A B S T R A C T
Right heart failure is the major cause of death in Pulmonary Artery Hypertension (PAH) patients but is not a
current, speciﬁc therapeutic target. Pre-clinical studies have shown that adrenoceptor blockade can improve
cardiac function but the mechanisms of action within right ventricular (RV) myocytes are unknown. We tested
whether the β1–adrenoceptor blocker metoprolol could improve RV myocyte function in an animal model of
PAH, by attenuating adverse excitation-contraction coupling remodeling. PAH with RV failure was induced in
rats by monocrotaline injection. When PAH was established, animals were given 10mg/kg/day metoprolol
(MCT+BB) or vehicle (MCT). The median time to the onset of heart failure signs was delayed from 23 days
(MCT), to 31 days (MCT+BB). At 23 ± 1 days post-injection, MCT+BB showed improved in vivo cardiac
function, measured by echocardiography. RV hypertrophy was reduced despite persistent elevated afterload. RV
myocyte contractility during ﬁeld stimulation was improved at higher pacing frequencies in MCT+BB.
Preserved t-tubule structure, more uniform evoked Ca2+ release, increased SERCA2a expression and faster
ventricular repolarization (measured in vivo by telemetry) may account for the improved contractile function.
Sarcoplasmic reticulum Ca2+ overload was prevented in MCT+BB myocytes resulting in fewer spontaneous
Ca2+ waves, with a lower pro-arrhythmic potential. Our novel ﬁnding of attenuation of defects in excitation
contraction coupling by β1–adrenoceptor blockade with delays in the onset of HF, identiﬁes the RV as a pro-
mising therapeutic target in PAH. Moreover, our data suggest existing therapies for left ventricular failure may
also be beneﬁcial in PAH induced RV failure.
1. Introduction
Pulmonary artery hypertension (PAH) occurs when the resistance of
the pulmonary vasculature increases, resulting in chronic elevated
afterload and subsequent right ventricle (RV) dysfunction. Available
therapies aim to reduce afterload by promoting vasodilation, however
there is no cure and novel treatments are needed [7,21]. RV failure is
the most common cause of death in PAH patients, but there is no
treatment that speciﬁcally addresses RV dysfunction [17]. Despite dif-
ferences in the structure and function of the RV and left ventricle (LV),
it has been proposed that established treatments for LV failure may be
beneﬁcial to the failing RV in PAH [21].
β-adrenoceptor blockers (BB) were once considered paradoxical but
quickly revolutionized the treatment of LV failure by delaying ven-
tricular remodeling and reducing mortality [6,14]. However, concerns
exist over the safety or beneﬁt of BB in PAH [31,34,42], and as such
they are not recommended [17,32]. However, PAH patients may re-
ceive BB for co-morbidities and recent small scale clinical trials have
demonstrated BB safety [1,19,39,40,11]. Pre-clinical studies have
shown BB are protective in animal models of PAH, by improving car-
diac capillary density, reducing inﬂammation and ﬁbrosis [4,12,33].
However, the eﬀect of BB treatment on the function of RV myocytes
from PAH animals has not been studied. The purpose of our study was
therefore to investigate the mechanisms by which improvements, in
response to BB treatment, may occur in the PAH myocardium.
Because of the myocardial focus of our study, we chose a β1-
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selective blocker (metoprolol) as this was predicted to target the
myocardium more selectively than carvedilol, which has mixed α and β
adrenoceptor actions [4] or nebivolol, which has intrinsic vasodilatory
pulmonary and systemic properties [33]. Metoprolol is a commonly
prescribed BB which reduces mortality in LV failure [44].We used the
monocrotaline (MCT) rat model of PAH as it is well established for the
study of RV failure [4,12,33,3,15,41]. MCT rats were treated daily with
metoprolol (MCT+BB) once PAH was established, to mimic the late
detection and treatment that usually occurs in human PAH.
Cardiac excitation contraction coupling plays a fundamental role in
pump function and defective Ca2+ handling and electrical remodeling
reduce contractility and increase electrical instability in RV failure
[3,15,41]. We tested whether actions of BB on the RV myocardium
attenuated Ca2+ handling and electrical abnormalities to facilitate en-
hanced RV function.
Chronic treatment with metoprolol delayed the onset of RV failure
signs in MCT rats, improved RV function and attenuated repolarisation
remodeling in vivo. There was reduced hypertrophy of RV myocytes.
Metoprolol improved the Ca2+ handling and contractility of isolated RV
myocytes from MCT rats, this was associated with preservation of
transverse (t)- tubule morphology, more homogenous Ca2+ release and
decreased susceptibility to (potentially arrhythmogenic) spontaneous
diastolic Ca2+ release. These data suggest the beneﬁcial eﬀects of BB in
PAH include actions on the mechanical and electrical activity of RV
myocytes and that RV treatment may be a valid addition to PAH
therapy.
2. Materials and methods
See online supplementary material for detailed methods.
Experiments were conducted with local ethical approval in accordance
with UK Home Oﬃce, European Parliament Directive 2010/63/EU
guidelines on the use of animals in research.
2.1. Animal model and β-blocker treatment
A 3-group experimental design was used, as employed previously by
other groups [4,12,33]. Male Wistar rats (200 g) received a single in-
traperitoneal injection of 60mg/kg MCT to induce PAH or an equiva-
lent volume of saline. Voluntary oral treatment with a sucrose solution
(vehicle) to saline (CON) or MCT-treated (MCT) animals or with 10mg/
kg/day metoprolol dissolved in sucrose solution (MCT+BB) was in-
itiated 15 days post-injection when PAH was established (Table S1).
The chosen dose was within the human equivalent dose used clinically
in LV failure (see supplementary methods). MCT rats were killed by
cervical dislocation, following concussion, upon showing signs of heart
failure. The primary indication of heart failure was>10 g weight loss
compared to the previous day or weight loss on consecutive days, ac-
companied by other indicative signs including dyspnoea, piloerection,
lethargy and cold extremities [18,27,30,37]. CON rats were killed on
the median (± 1) survival day of MCT rats. MCT+BB rats used for the
survival study (see Fig. 1A) were killed when heart failure signs de-
veloped. In other experiments MCT+BB rats were killed on the median
(± 1) survival day of MCT rats unless heart failure signs occurred
earlier.
2.2. In vivo monitoring
Transthoracic RV echocardiography was performed under 1.5%
isoﬂurane anesthesia prior to the ﬁrst dose of BB or sucrose only
treatment on day 15, and again on the terminal day. To monitor ECGs
and activity in conscious, unrestrained animals, rats were implanted
with telemetric probes under anesthesia (2–3% isoﬂurane) using aseptic
techniques. Postoperative analgesia was given by subcutaneous injec-
tion of Buprenorphine (Vetergesic 0.1 mg/kg) with the antibiotic
Baytril (20mg/kg).
2.3. Histology
10 μm thick transverse cryosections of the RV free wall were stained
with ﬂuorescein-conjugated lectin. Myocytes were manually identiﬁed
in lectin-stained sections by their characteristic oval-shape when cut in
cross section. The interior cell boundary of cells was manually identi-
ﬁed and traced by an experimenter blinded to the group condition.
2.4. Single myocyte studies
Single ventricular myocytes were isolated by enzymatic digestion
according to [28] and modiﬁed to allow isolation of separate RV and LV
myocyte populations. Intracellular Ca2+ was measured in myocytes
either loaded with 2 μmol/L Fura-4-AM for whole cell epi-ﬂuorescence
at 37 ± 1 °C or 6 μmol/L Fluo-4-AM for confocal experiments at
22 ± 1 °C. Sarcomeric shortening was measured using IonWizard
software (Ionoptix, Milton USA) during external ﬁeld stimulation.
Spontaneous Ca2+ sparks were recorded in Fluo-4 loaded cells using
confocal microscopy in linescan mode (188 lines/s, pixel size 0.2 μm).
The sarcolemma and t-tubule system of isolated myocytes was stained
using di-8-ANEPPS (5 μmol/L) and visualized using confocal micro-
scopy. Sodium-calcium exchange (NCX) current was recorded in dis-
continuous voltage clamp as the tail current at −80mV elicited by a
20ms depolarizing step from −80mV to +10mV, following 300ms
priming pulses.
2.5. Measurement of mRNA by RT-PCR and protein by Western blotting
Total RNA extraction from RV homogenates was performed using a
Qiagen mini-kit. Transcript expression was normalized to the house-
keeping genes 18S and GAPDH in the test samples and then made re-
lative to the normalized signal level in the corresponding calibrator
sample.
Myocardial tissue was prepared for Western blotting as described
previously [15] and probed for amphiphysin II (BIN-1), junctophilin 2
(JP2), and Ca2+-handling proteins phospholamban (PLN) and sarco
(endo)plasmic reticulum Ca2+ ATPase 2A (SERCA) and normalized to
GAPDH.
2.6. Statistics
Data are presented as mean ± s.e.m. Details of all statistical tests
are given in the supplementary methods. P < .05 was considered sta-
tistically signiﬁcant. The term, intermediate, is used when comparison
of CON vs MCT yields a statistical diﬀerence and data mean for
MCT+BB has moved towards that for CON such that MCT+BB is
statistically diﬀerent to neither CON nor MCT.
3. Results
3.1. BB delayed the onset of heart failure
The development of heart failure signs was delayed in MCT+BB
rats compared with MCT rats (Fig. 1A). Signs presented with a median
of 23 days in MCT rats, whereas using the same criteria, signs presented
with a median of 31 days in BB treated rats (P < .01 vs MCT). Al-
though BB delayed the onset of heart failure, once developed, the
phenotype of failing MCT and failing MCT+BB were not diﬀerent.
3.2. Eﬀect of BB treatment on RV function and electrical remodeling in vivo
The presence of PAH and RV hypertrophy and dilation in MCT
treated animals, prior to BB treatment, was conﬁrmed by in vivo
echocardiography (Table S1). Eﬀective sympathetic blockade by BB
treatment was demonstrated by a lack of physical activity-related in-
crease in heart rate, measured by telemetry in freely moving rats (Fig.
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S1). To assess whether BB improved RV function, CON and MCT+BB
animals were studied 23 ± 1 days after a single injection of saline or
MCT and compared to vehicle treated MCT rats on the day heart failure
signs developed.
MCT animals displayed characteristic increases in lung:body weight
RV:body weight and RV:LV+ septum weights compared to CON ani-
mals (Table S2). Echocardiography (Fig. S2) revealed increased pul-
monary artery pressure, RV free wall thickness and increased RV dila-
tation in MCT rats compared to CON (Fig. 1B, Table S3). MCT rats had
decreased RV stroke volume (Fig. 1C, Table S3) and depressed cardiac
output (Fig. 1D, Table S3). BB treatment reduced RV wall thickness and
increased SV (P < .05) compared with MCT, although cardiac output
was not signiﬁcantly increased (P= .09, Fig. 1B–D). A 10–15% re-
duction in mean RV:LV+ septum ratio, pulmonary artery pressure and
RV internal diameter compared to MCT animals, was not statistically
signiﬁcant (Table S2, Table S3). Lung weights were not changed by BB
treatment (Table S2).
Telemetric measurement of ECGs in conscious unrestrained animals
during their inactive period on the ﬁnal experimental day showed a
decrease in RR interval (P < .05) and increase in QT interval
(P < .001) in MCT compared with CON, both these eﬀects were atte-
nuated by BB treatment (Fig. 2A, B).
Prolongation of QT interval represents a longer repolarization and
consistent with this, we observed decreased mRNA expression of genes
encoding for repolarizing K+ channels (Ito, IK and IK1) in MCT compared
to CON (Fig. 2C). Expression of the Kir2.1 gene for IK1 was decreased in
MCT (P < .05) but not (P > .05) in MCT+BB. Mean mRNA expres-
sion for both Kv4.2 and Kv4.3 (responsible for Ito) were decreased in
MCT and MCT+BB. Expression of mRNA for K+ channel sub-units/
chaperones KChap and KChip2 was not changed but the expression of
Ito regulator Nfat3 was decreased in MCT (P < .05) but not (P > .05)
in MCT+BB (Fig. 2D).
3.3. BB decreased RV myocyte hypertrophy
Fig. 3A shows exemplar sections of RV showing myocyte boundaries
demarcated by ﬂuorescent lectin boundaries. Consistent with measures
of RV wall thickness (Fig. 1B), RV myocyte cross sectional area was
greater in MCT than CON and MCT+BB (reduced with BB treatment
by 12%, P < .05 vs MCT, Fig. 3B). To support this observation, we also
measured the geometry of single isolated RV myocytes. RV myocyte
width and volume were greater in MCT cells, in comparison dimensions
in MCT+BB cells were reduced by 11% and 16%, respectively (Fig. 3C
&D). The width and volume of LV myocytes were not diﬀerent between
groups (Table S4).
3.4. BB improve RV myocyte contractile response to increased demand
To investigate whether RV myocyte contractility was improved by
BB, Ca2+ transients and sarcomere shortening were recorded in RV
myocytes paced between 1 and 7 Hz (Fig. 4A,D). At 1 Hz, Ca2+ tran-
sient amplitude was greater (P > .05) in MCT than CON and
MCT+BB (Fig. 4B). Ca2+ transient amplitude fell steeply at higher
pacing frequencies in MCT cells, in contrast to a stable Ca2+ transient in
CON myocytes. The Ca2+ transient of MCT+BB myocytes was sig-
niﬁcantly greater than MCT at 7 Hz (Fig. 4C). Sarcomere shortening
reﬂected the changes in Ca2+ transient amplitude at each pacing fre-
quency (Fig. 4E&F). Some myocytes could not be paced at 7 Hz re-
sulting in the formation of Ca2+ transient and mechanical alternans
(Fig. 4G): 98% (48/49) of CON cells contracted regularly at 7 Hz,
whereas 74% (35/47) of MCT+BB myocytes and 61% (27/44) of MCT
myocytes could be paced at 7 Hz (P < .001, Chi2 test). The contrac-
tion-frequency relationship of LV cells was similar between groups (Fig.
S3). Compromised Ca2+ uptake into the sarcoplasmic reticulum (SR)
could impair contraction at higher frequencies and we observed de-
creased protein expression of the SR Ca2+ uptake pump, SERCA in MCT
rats. This was partially restored by BB treatment (P < .05 MCT vs
MCT+BB, Fig. 4H). Expression of the SERCA inhibitory protein PLN
was decreased in both MCT and MCT+BB rats compared with CON
(Fig. 4I).
3.5. BB prevented t-tubule remodeling and enhanced Ca2+ release in single
RV myocytes
T-tubule structure is important for coordinated SR Ca2+ release.
Fig. 5A shows exemplar confocal images of the t-tubule system (upper
panels), and following skeletonization to visualize the predominant
direction of tubules (lower panels). It was apparent that tubules in CON
myocytes followed a regular striated pattern in the transverse direction,
whereas MCT tubules were disorganized, with more longitudinal ele-
ments. BB treatment preserved t-tubule regularity, as indicated by
greater fast Fourier transform power (Fig. 5B) and predominant
Fig. 1. Metoprolol delayed the onset of heart failure
in rats with pre-existing PAH. A The median day to
failure signs was increased from 23 to 31 days post
MCT injection (N=12 MCT, 15 MCT+BB rats, **
P < .01, Mantel-Cox test). Echocardiography mea-
surements of RV function were performed on the day
of heart failure signs (MCT) or the median survival
day of MCT rats (CON and MCT+BB). B RV wall
thickness was reduced in MCT+BB rats compared
to MCT, indicating attenuation of hypertrophy. C
Stroke volume was increased by BB D Cardiac output
was not signiﬁcantly increased with BB (P= .09 vs
MCT). B-D N=9 CON, 7 MCT, 5 MCT+BB rats.
One-way ANOVA. * P < .05, *** P < .001.
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Fig. 2. BB attenuated electrical remodeling.
Telemetric recording of ECGs during the light (in-
active) period on day 1, day 15 (prior to vehicle or
BB treatment) and ﬁnal experimental day. A On the
ﬁnal day there was a decrease in RR interval in MCT
animals compared to CON, this eﬀect was attenuated
by BB treatment. B BB treatment signiﬁcantly re-
duced the QT prolongation seen in MCT. C Final day
mRNA levels for channels carrying repolarising K+
currents were signiﬁcantly reduced in MCT com-
pared with CON. For the main channel carrying IK1
there was intermediate expression in MCT+BB an-
imals for Kir2.1. D Final day mRNA levels for K+
channel subunits KChap and KChIP2 did not vary
between groups but the expression of the Kv reg-
ulator Nfatc3 was reduced in MCT compared with
CON, while MCT+BB hearts showed intermediate
levels. A, B N=9–12 animal in each group, two-way
ANOVA. C, D N=10 animals in each group, one-
way ANOVA. *P < .05, **P < .01, ***P < .001.
Fig. 3. BB attenuated RV myocyte hypertrophy. A Exemplar images of RV cryosections stained with lectin to ﬂuorescently label the membrane of myocytes.
Capillaries are also stained by lectin and appear as dense spots of labelling. A selection of myocytes (asterisks) and capillaries (arrows) are indicated. BMean myocyte
cross sectional area was greater in MCT compared to CON and MCT+BB. The mean value of 2–5 RV sections from each heart were used for statistical analysis. Data
represents means from N=6 rats per group. C The cell width and D cell volume of isolated myocytes was greater in MCT than CON and MCT+BB. B N=6 rats per
group, C,D N=6–9 rats per group, myocyte numbers given in the ﬁgure. One-way ANOVA. *P < .05, **P < .01, ***P < .001.
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transverse orientation (Fig. 5C). T-tubule formation and maintenance is
associated with BIN-1 and junctophillin-2 (JP-2) proteins. Fig. 5D
shows representative Western blots of BIN-1 and JP-2. BIN-1 expression
was reduced in the RV of MCT rats compared to CON (P < .05)
(Fig. 5E). JP-2 expression was not signiﬁcantly reduced in MCT com-
pared to CON (Fig. 5F). Fig. 5G shows exemplar Ca2+ transients re-
corded using confocal line scanning, contrasting the uniform Ca2+ re-
lease in the CON and MCT+BB cells with the scalloped appearance of
the MCT Ca2+ transient. Dyssynchrony of Ca2+ release in MCT cells
was reduced by BB treatment (P < .05 vs MCT) (Fig. 5H). The time to
peak Ca2+ was longer in MCT compared to CON (P < .05), but was
intermediate in MCT+BB cells (i.e. not signiﬁcantly diﬀerent to CON
or MCT) (Fig. 5I). Improved t-tubule regularity and more coordinated
SR Ca2+ release could contribute to the improved contractility of
MCT+BB cells.
3.6. Attenuation of spontaneous diastolic Ca2+ release by BB
Spontaneous Ca2+ release can provoke arrhythmias. Fig. 6A (left
panel) shows a spontaneous Ca2+ wave (SCW) propagating across a
cell, the average ﬂuorescence in the trace beneath is rounded with a
slow upstroke. Fig. 6A (right panel) shows a SCW which triggers a
synchronous Ca2+ release (termed whole cell event, WCE) throughout
the cell. The corresponding line plot is distinguished by a rapid com-
ponent to the upstroke and larger amplitude. Comparable events were
measured with epi-ﬂuorescence in Fura-4 loaded myocytes. The oc-
currence of SCWs and WCEs was measured in unstimulated myocytes
during 60 s rest following 5 Hz stimulation (Fig. 6B). The combined
frequency of SCWs +WCEs (Fig. 6C) and the proportion that were
WCEs (Fig. 6D) was decreased in MCT+BB myocytes compared with
MCT myocytes (P < .05).
The precursor to Ca2+ waves are Ca2+ sparks. Fig. 7A shows
Fig. 4. BB improved RV myocyte contraction-frequency relationship. A Representative traces of Ca2+ transients at diﬀerent stimulation frequencies. B Ca2+ transient
amplitude of RV myocytes ﬁeld stimulated at 1 Hz was greater in MCT than CON and MCT+BB. C The Ca2+ transient amplitude remained stable in CON cells as
pacing frequency was increased, whereas it progressively declined in MCT. Ca2+ transient amplitude was greater in MCT+BB than MCT at 7 Hz. The number of cells
that could be paced at 7 Hz is shown. D Representative traces of unloaded sarcomere shortening in a separate group of cells without Fura-4 at diﬀerent stimulation
frequencies. E Shortening at 1 Hz was not diﬀerent between groups. F Changes in sarcomere shortening with increased stimulation frequency reﬂected the changes in
Ca2+ transient amplitude. Shortening in MCT+BB cells was greater than MCT at 7 Hz. G Example recording of a MCT cell unable to regularly pace at 7 Hz due to the
emergence of Ca2+ release (upper panel) and sarcomere shortening (lower panel) alternans. H,I Representative Western blots of SERCA2a, PLN and GAPDH. Note
diﬀerence in group orders between blots (upper panels) and data (lower panels). H There was a reduction in protein expression of SERCA2a in MCT RV that was
partially restored by BB. I There was a reduction in protein expression of PLN in the RV of MCT and MCT+BB hearts. N=6 rats per group. B,E,H,I one-way
ANOVA, C,F two-way ANOVA. *P < .05, **P < .01 vs CON, †P < .05 vs MCT+BB.
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exemplar line scan recordings of Ca2+ sparks at rest (outlined in white).
The mean Ca2+ spark frequency was greater in both MCT and
MCT+BB RV cells than CON (P < .05, Fig. 7B) without statistically
signiﬁcant changes in other Ca2+ spark properties (Fig. 7 C-E). We used
a modeling approach to investigate the reasons for the diﬀerences in
SCW+WCE frequency between MCT and MCT+BB myocytes. A ﬁrst
approximation of the likelihood of Ca2+ wave initiation was derived
according to the reported sensitivity of rat RyR open probability (Po) to
cytosolic [Ca2+] [25]. Fig. 7F shows simulated Ca2+ sparks constructed
from the mean values in Fig. 7C-E. The time-varying RyR Po was cal-
culated at a distance equal to the mean resting sarcomere length of each
group from the model spark centroid (white dashed line) (Fig. 7F and
Table S4). Fig. 7G shows that modest changes in Ca2+ spark properties
and a shorter resting sarcomere length increased peak RyR Po in MCT
cells by 130% compared to CON. In contrast, the slightly decreased
spark size and increased sarcomere length in MCT+BB cells increased
RyR Po by only 60% compared to CON. Therefore, despite no change in
Ca2+ spark frequency, compared with MCT, this simple model predicts
that the likelihood of SCW+WCE occurring should be decreased in
MCT+BB cells.
A greater proportion of Ca2+ releases were WCEs in MCT myocytes
and this was decreased by BB treatment (Fig. 6D). This eﬀect may be
related to a greater SR Ca2+ load in MCT myocytes and a normalization
of SR Ca2+ load by BB treatment, as revealed by rapid exposure to
caﬀeine (Fig. 8). When subjected to the same SR loading protocol MCT
myocytes generated greater (P < .05) inward NCX current than CON
myocytes (Fig. S4). An increase in SR Ca2+ release will generate in-
creased inward NCX current, which may provoke Ca2+-induced ar-
rhythmias (see Section 4.4).
4. Discussion
Here we show for the ﬁrst time that β1-adrenoceptor blockade at-
tenuated hypertrophy, prevented t-tubule remodeling and improved
Ca2+ handling in RV myocytes of PAH animals. These eﬀects resulted in
an improved contractile response to increased stimulation frequency
and less susceptibility to potentially arrhythmic, spontaneous diastolic
Ca2+ release. We also report the novel ﬁnding that β1-adrenoceptor
blockade attenuated repolarization abnormalities caused by PAH.
Our study was focussed upon the myocardium and for this reason
Fig. 5. T-tubular structure was preserved and SR Ca2+ released synchronised by BB. A Binary images of t-tubule morphology (top) and following skeletonization
(bottom). B The regularity of t-tubules (fast Fourier transform power) was reduced in MCT compared to CON but preserved by BB treatment. Myocyte number given
in the ﬁg. C Tubule orientation was mainly transverse in CON and MCT+BB myocytes but more longitudinal in MCT myocytes. D Representative Western blots of
BIN-1, JP2 and GAPDH. Note diﬀerence in group orders between blots and data, protein ladders separate group samples for BIN-1. E Protein levels of BIN-1 were
reduced in MCT and MCT+BB. F JP2 was not diﬀerent between groups. G Confocal linescan recordings show spatial non-uniformities in Ca2+ transients from MCT
cells. H Ca2+ release was more heterogeneous in MCT cells. IMean time to peak Ca2+ was slower in MCT. B,C, N=3–4 rats per group, E,FN=6 rats per group, H,I,
N=5–8 rats per group. B,C,F,H,I one-way ANOVA, E non-parametric ANOVA. *P < .05.
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Fig. 6. Frequency of spontaneous Ca2+ release was
decreased by BB. A Contrasting morphologies of
spontaneous Ca2+ waves (SCWs) and whole cell
events (WCEs) in linescan (upper traces) and spa-
tially averaged traces (lower traces) from un-
stimulated MCT RV myocytes. B Ca2+ release events
during a 1min quiescent period showing SCWs (open
arrows) and WCEs (ﬁlled arrows). C. BB attenuated
the total (SCW+WCE) number of Ca2+ releases,
myocyte numbers given in the ﬁg. D BB attenuated
the proportion of WCEs. N=5–6 rats per group. C
one-way ANOVA, D Fisher's Exact test. *P < .05.
Fig. 7. Increased frequency of Ca2+ sparks in PAH. A Exemplar confocal linescan recordings showing Ca2+ sparks (outlined by boxes). BMean Ca2+ spark frequency
was signiﬁcantly increased in MCT cells and was not aﬀected by BB treatment. Myocyte numbers given in the ﬁgure. There were no statistically signiﬁcant diﬀerence
between the mean C Ca2+ spark amplitude, D full width at half-maximum (FWHM) and E duration of the 3 groups. F To estimate the likelihood of a Ca2+ spark
activating RyR clusters at a neighbouring junction (i.e. spontaneous Ca2+ wave initiation), model Ca2+ sparks were created using the mean properties of CON, MCT
and MCT+BB Ca2+ sparks in (C-E). The cytosolic [Ca2+] at distances corresponding to the mean resting sarcomere length of each group (dashed line) was
calculated. G The peak time-varying RyR open probability (RyR Po) in the neighbouring junction was greatest in MCT, but was reduced by BB treatment. Data in (G)
is normalised to CON. N=5–8 rats per group, one way ANOVA. *P < .05, **P < .01.
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we chose to use a β1-adrenoceptor blocker, the major adrenoceptor type
in the myocardium. Other BBs have additional actions, e.g. carvedilol,
has mixed α and β actions [4] and nebivolol has intrinsic vasodilatory
pulmonary and systemic eﬀects [33]. It is possible that these eﬀects
may be additionally beneﬁcial in PAH, as vasodilation of the pulmonary
vasculature is a central strategy in current PAH therapy.
4.1. In vivo cardiac function and electrical remodeling
The improvement in stroke volume and trend for increased cardiac
output (P= .09) in MCT+BB rats occurred in the absence of sig-
niﬁcant RV afterload reduction, similar to reports using other BB
[4,12,33]. This suggests the protective eﬀects of metoprolol are medi-
ated through direct actions on the myocardium, rather than secondary
to pulmonary responses, and are attributable to its β1-selectivity. In
conscious animals, metoprolol treatment did not reduce resting heart
rate, but did block activity-induced increase in heart rate, this is con-
sistent with the eﬀect of bisoprolol reported by [12]. In conscious MCT
rats, heart rate was increased compared to CON (Fig. 2A), conversely,
under anesthesia, heart rate was decreased in MCT and MCT+BB rats
(Table 3), which is consistent with the observations of [3]. This in-
creased sensitivity to anesthesia should be considered when inter-
preting cardiac output data.
In human PAH patients QT interval prolongation correlated with
mortality [35] and we found BB attenuated QT prolongation. BB
treatment did not cause statistically signiﬁcant increases in mRNA ex-
pression of the main channels that carry Ito (Kv4.2 and Kv4.3) however
there was a consistent graded expression (CON>MCT+BB > MCT)
of mean mRNA for Kv4.2, Kv4.3 and intermediate expression of both
the Ito regulator Nfatc3 [36] and the Kir2.1 channel (IK1). QT pro-
longation in MCT animals is linked to decreased expression of Kv
channel mRNA, therefore our observations indicate a mechanism
whereby QT prolongation may be attenuated by BB via changes in
expression of several Kv channels.
4.2. Decreased RV hypertrophy with BB
Measurement of RV myocyte size and RV wall thickness by echo-
cardiography indicated a reduction in RV hypertrophy with BB.
Although the decrease in RV:body weight with BB treatment was not
statistically signiﬁcant the mean change (11%) was similar to the 15%
decrease in myocyte size. By necessity, RV free walls were weighed
following exposure to collagenase, prior to dispersion into single
myocytes. Diﬀerences in the response of tissue to digestion may obscure
smaller diﬀerences in RV weight between MCT and MCT+BB.
The hypertrophic response to pressure overload is considered a
compensatory mechanism to normalize elevated wall stress [20].
However, blocking the hypertrophic response does not necessarily
worsen outcomes in LV failure [10,38]. Furthermore, myocardial
hypertrophy is associated with increased incidence of death [26],
possibly by reducing coronary perfusion, increasing oxygen diﬀusion
distances, or increasing energy expenditure.
4.3. BB improved the inotropic response of RV myocytes to increased
demand
A deﬁnition of heart failure is the inability to cope with increased
demand (e.g. the NYHA classiﬁcation). In the MCT model this presents
as a steeply negative contraction-frequency relationship linked to a fall
in the amplitude of the Ca2+ transient [3,15]. Disruption of the t-
system uncouples LTCC and RyR resulting in inhomogeneities in Ca2+
release which slow the rate of force development [13]. Loss of t-tubules
in human LV failure is associated with reduced contractility of the
ventricle [9]. We observed a loss of regularly spaced t-tubules in MCT.
T-tubule formation and maintenance is linked to BIN-1 and JP2 [8] and
in MCT myocytes we observed a reduction in BIN-1 protein, as reported
in LV failure [8], with a trend (mean CON>MCT+BB > MCT) for
both BIN-1 and JP2. The downregulation of SERCA in MCT is likely to
limit the ability to cycle Ca2+ normally and this too was improved by
BB. In addition we have previously shown that the contraction-fre-
quency relationship in MCT myocytes is inﬂuenced by BB via expres-
sion of creatine kinase [15,16]. Repolarization proﬁle can modulate
Ca2+ handling [5] and we have shown that in MCT myocytes the sti-
mulation frequency dependent fall in contraction is, at least in part,
caused by the stimulation frequency dependent fall in action potential
duration (APD) [3,22]. Therefore, the prolonged APD and QT interval
occurring in the MCT model may facilitate greater SR load through
enhanced Ca2+ entry, while steeper APD restitution contributes to the
steeper stimulation frequency dependent fall in Ca2+ transient ampli-
tude [3,22]. Mechanical alternans are a consequence of Ca2+ transient
alternans (Fig. 4G) which are themselves provoked either by dysfunc-
tion of Ca2+ uptake/release and/or by APD alternans, see [3]. These
responses may be improved by the attenuation of QT prolongation by
BB. Thus, cumulative factors inﬂuencing myocyte structure, Ca2+
handling protein expression, and metabolic and electrical activity are
likely to have improved myocyte contractile function.
4.4. Improved diastolic Ca2+ handling following BB
MCT myocytes produced more total spontaneous Ca2+ releases
(SCWs+WCEs), with a greater proportion of WCEs; both types of Ca2+
release were reduced by BB. RyR are clustered at the sarcomeric Z-line
[23] and a shorter SL will bring Ca2+ release units of adjacent Z-lines
closer together and increase the probability of wave initiation and
propagation [24]. For Ca2+ sparks to initiate SCW, they must raise
cytosolic Ca2+ suﬃciently to activate RyR clusters ~1.9 μm from the
original spark site, since RyR Po is thought to depend on cytosolic
[Ca2+]~2.8 [25]. Assuming isotropic Ca2+ diﬀusion in the cytosol [2],
our modelling predicts that the modest changes in Ca2+ spark char-
acteristics we observed, together with increased RyR spacing in re-
sponse to BB are suﬃcient to decrease RyR open probability and thus
the chances of Ca2+ wave propagation.
WCEs are thought to be linked to delayed after depolarization
(DAD) arrhythmias. Ca2+ induced DADs are driven by inward NCX
current and the greater the SR load, the greater the potential for Ca2+
release and subsequent depolarizing NCX current (Fig. S4). The re-
sultant magnitude of depolarization for a given NCX current density is
dependent upon resting membrane stability, which is determined lar-
gely by IK1 current carried through Kir2.1 channels [29]. We have
shown that in MCT myocytes there is an increase in SR load (Fig. 8) and
NCX current (Fig. S4) and have recently reported that membrane sta-
bility is decreased in these cells [22]. Thus, the decrease in WCEs in
response to BB can be explained by the decrease in SR Ca2+ load and
intermediate level of Kir2.1 expression in MCT+BB myocytes.
Fig. 8. Increased SR load in MCT cells is reversed by BB. A SR Ca2+ content was
estimated during steady state pacing at 5 Hz by rapid application of caﬀeine
(indicated by arrow) to deplete SR stores. B SR load was increased in MCT
compared to CON, and returned to normal levels by BB. Myocyte numbers given
in ﬁg. N=5–6 rats per group, one way ANOVA. *P < .05.
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4.5. Limitations
The MCT model is used extensively to study the eﬀects of PAH on
the RV due to the reliable induction of heart failure, although its exact
mode of action is not fully understood and vascular remodeling does
not lead to plexiform lesions as seen in human patients of PAH, for
recent reviews of the model see [18,27,30,37]. We cannot discount
systemic eﬀects of BB, however the LV, which was exposed to the same
circulating levels of metoprolol as the RV, was unaﬀected by BB
treatment (Table S4 & Fig. S3). Our Ca2+ spark model was intended to
test the role of Ca2+ spark properties and cell geometry on SCW in-
itiation; changes in RyR sensitivity or cytosolic [Ca2+] may further
inﬂuence wave initiation.
4.6. Conclusions and Implications
The need to study the speciﬁc nature of RV pathophysiology has
been highlighted [43]. Notwithstanding this important point, our novel
observations show beneﬁcial eﬀects of BB on RV structural, mechanical
and electrical remodelling and on intracellular Ca2+ handling. Despite
the diﬀerent structure and operating environments of the RV and LV,
existing treatments for LV failure may be useful adjuncts to therapies
targetting pulmonary vasculature dysfunction in RV failure resulting
from PAH.
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